20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Document Security Systems, Inc. (NYSE:DSS), subsidiary Impact Biomedical, Inc, along with its scientific research partner Global Research and Discovery Group Sciences, GRDG, announced encouraging results from clinical tests of its 3FDB (DEET Booster) technology.
- The results suggest that 3FDB can boost the effectiveness of mosquito repellants, specifically DEET. Working with an independent lab, GRDG conducted three tests involving the mosquito (Aedes aegypti).
- Daryl Thompson, Director of Scientific Initiatives at GRDG, stated, "These tests represent an important development in addressing mosquito-borne diseases and could signal a new frontier of protection strategies."
- Recently, Impact Biomedical and GRDG received a U.S. Patent for 3FDB (US 10,966,424), a Functional Fragrance Formulation, which increases the current mosquito repellants' effectiveness through light and a fragrant compound derived from botanical oils.
- Price Action: DSS shares are trading lower by 3.16% at $1.2686 on the last check Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!